Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HC- every time a mkt maker makes a sale to a retail or instl client and he doesnt own the shares in inventory ....that is a short sale and is a large part of the short volume...... so with a decent % move and volume like yesterday ......short volume will be higher
Thx T great stuff
family office types gotcha thx bud
GLG- Im a fan but Why would they tell you if you are going to put the info on a message board which could cause price to go up? If any of my friends or ex hedge fund clients knew or thought I did that the relationship would be over. No disrespect intended just curious
Where did you get that info that they sold 50k ?
maybe you can buy The Princeton and the Little P
Hard to buy anything under $2
GLG- do you own any of other warrants like TIXXF ? trades around 4 cts
new hire -
DJIA: 26,922.12 -43.88 (-0.16%) | NASDAQ: 8,161.791 -8.44 (-0.10%) | S&P 500: 2,990.41 -5.41 (-0.18%) —Markets closed
Print Format Change Text Size:
Default text sizeA Larger text sizeA Largest text sizeA
Titan Medical Names Surgical Robotics Sales Veteran Chad A. Zaring as its Chief Commercial Officer
BY Business Wire
— 7:30 AM ET 07/08/2019
TORONTO--(BUSINESS WIRE)-- (July 8, 2019) – Titan Medical Inc. ( TTXXF
Loading...
Loading...
) (“Titan” or the “Company”) , a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that Chad A. Zaring has joined the Company as chief commercial officer, a new position. Mr. Zaring has deep experience developing and executing commercial strategies and driving sales for leading surgical robotics companies and will be responsible for the launch of Titan’s single-port robotic surgery system following receipt of regulatory clearances. He will report to David McNally, Titan’s chief executive officer.
Mr. Zaring joins Titan from Medtronic, where since September 2017 he was vice president robotics, imaging and navigation. Prior to Medtronic, he was with Mazor Robotics from May 2015 through the initiation of a Global Distribution Agreement in September 2017 that led to its subsequent acquisition by Medtronic. As vice president, national accounts and later vice president, U.S. sales, he developed the capital sales teams, established new sales channels and consistently exceeded sales goals. Earlier in his career, from 2004 to April 2015 Mr. Zaring held positions of increasing responsibility at Intuitive Surgical, and was a member of the leadership team that executed early and mid-stage adoption of their robotic surgery system across multiple surgical disciplines.
“Chad is the ideal professional to lead the commercialization of our single-port robotic surgical system, and we are thrilled he has chosen to join Titan Medical,” said Mr. McNally. “The timing couldn’t be better. We are at an inflection point in our company’s development as we prepare for successful execution of preclinical and clinical studies that will permit us to file for regulatory clearances both in the U.S. and the EU by the end of the year. We look forward to having such a talented and broadly experienced individual as Chad execute our sales strategy and further strengthen our in-house robotic commercial launch expertise.”
“I am excited to be joining Titan Medical ( TTXXF
Loading...
Loading...
) and to advance my passion of introducing disruptive and life-changing technology, working to commercialize an innovative single-port robotic surgical system,” said Mr. Zaring. “I believe that single-port robotic surgery will be the next frontier in several surgical disciplines. I am committed to delivering on Titan’s vision of single-port robotic surgery with the highest standards and with relentless focus on our customers who will help us drive technology adoption. Titan will make an important contribution to patient health while addressing surgeon desires and filling a significant gap in the market landscape. Titan has already set a thoughtful, early commercial plan by initially targeting benign gynecologic indications and subsequently adding more applications over time.”
Mr. Zaring began his career at Merrill Lynch in 1999 as a financial sales consultant. He later held sales positions at Merck and Co. and at Ethicon Endo-Surgery, a Johnson & Johnson
They do that in hope of getting future investment banking business from TRXC. If TRXC does a secondary or anything banking related, they hope to be included. It is a game all these companies play
They announced DF right in front of BB conference too. Well played by mgmt. They will have lots to talk about at conference
thats it? you wouldnt disclose that?
if its on bloomberg...then its public info....can u disclose please ?
Has any news hit yet? I cant find anything ...... nice to see plus signs and watch shorts get squeezed for a change
great post thank you Mustang
Quid- Your post was the last one up ( most current) ....I posted it for everyone. - I did not insinuate anything. This is the second or third time I posted on this topic I dont engage in personal stuff on here. I just try post things that may benefit everyone. You are incorrect
From Fidelity in regard to loaning shares out for short sellers.
Looks like Demand has dropped after deal closed was 62% last week now 55 1/2 %................ I will NOT be participating
Thank you for your interest in Fidelity's Fully Paid Lending Program. Attached, please find some information about the opportunity. The program fact sheet, Master Securities Lending Agreement (MSLA), and collateral documents are all included. The MSLA governs the securities lending relationship between you and Fidelity and the Collateral Appointment Letters provide an overview of the services that Wells Fargo, Bank of America and Union Bank provide as collateral agents. The other documents are for informational purposes and do not require your signature.
Currently, the following positions and rates could apply (subject to change based on market conditions):
TMDI – 55.5% (Full disclosure – we have been seeing demand for shares of TMDI taper off here recently in the lending market)
im at 2.85 bidds running out of ammo$
Hi Adrock.....Did you get that info from Northland? Thx in advance
trying to buy under $3 here.....nothing for sale for last 15 mins
My broker just called looking for TMDI shares to lend to short sellers claiming it is very hard to borrow now. Anyone else getting those calls?
Essex county in the house!!!
Price action this am is great compared to past deals. Given the fact that it priced so quickly (and stock is above $3.40 with not much for sale out there ) compared to past history makes me this they have the whole offering placed with buyers which is huge. (more institutional support)
grabbed 4k too then it dried up under $3.50
Hope it closes before this but "It is expected that closing of the Offering will occur on or about March 21, 2019, or such other date or dates as the Company and the Agent may agree."
The Securities and Exchange Commission (SEC) has set rules to ensure that employees are not at a disadvantage during a blackout period. The SEC prohibits any director or executive officer of an issuer of any equity security from purchasing, selling or otherwise acquiring or transferring securities during a pension plan blackout period.
https://finance.zacks.com/blackout-period-8161.html
or
https://www.investopedia.com/ask/answers/08/blackout-period.asp
If you work for a company that's publicly traded, you could be subject to blackout periods during which you're not allowed trade the company's stock. You might have access to nonpublic information, with a potential for illegal insider trading. A blackout period is generally part of a company's internal policy. It's meant to prevent corporate insiders from unfairly benefiting -- intentionally or inadvertently -- from trades in the stock market. A company may impose a blackout period only on key executives, or it may apply it to a broader group of employees.
You are incorrect. There is a blackout period for "every" public company usually 2-3 weeks before reporting earnings and a week -2 weeks after the news is released.
T- What broker allows you to buy them in Canada? I use Fidelity and I cannot buy Canadian warrants. I did get hit on a low ball bid in TIXXF ( G warrants) at $0.0367 which was surprising
It may not be happening as quickly as everyone would like but these guys are playing the long game which in my humble opinion makes them more attractive to any potential acquirer.
T- I bought some G warrants around 4 1/2 cents ( TIXXF) they arent very liquid in US took about a month
just hit about ten mins ago...
Titan Medical Expands Global Intellectual Property Portfolio to 30 Patents Issued and 75 Pending with Receipt of First Patent in China
BY Business Wire
— 9:02 AM ET 02/27/2019
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (TTXXF) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 30 issued patents and 75 pending applications through the recent granting and filing of patent applications directed at aspects of its innovative robotic surgery program. Included in the recent patent grants is the Company’s first patent in China titled “Articulated Tool Positioner and System Employing Same,” for which the Company announced a notice of allowance in December 2018
The recently granted Chinese patent describes the smooth and continuously curved articulation of a robotic instrument to position and orient an end-effector in multiple degrees of freedom. The continuous curve architecture was designed to provide several advantages, including facilitating a central lumen that extends through the instrument to enable an independent roll of the end-effector, and providing for a multitude of end-effectors and advanced tools. Corresponding patents have been granted in Europe, Canada and Japan, and further applications are pending in several countries including the U.S.
“The continued expansion of our intellectual property portfolio further strengthens Titan’s position as an innovative leader in single-port robotic surgery technology,” commented David McNally, President and CEO of Titan Medical (TTXXF). “I commend Jasminder Brar, our Director of Strategic Development and Intellectual Property, on formulating and leading the successful execution of our IP strategy to enable Titan to protect its intellectual property in major markets around the world.
“While our initial focus for commercialization is the U.S., we remain committed to protecting our intellectual property in major markets to secure the long-term potential of the global surgical robotics opportunity for Titan or any commercial partners. We believe our system offers advanced technology in single-port robotic surgery, which could ultimately play a substantial role in expanding robotic surgery with the goal of improving patient outcomes,” he added.
As mentioned a few days ago by a few peeps...Zacks is rubbish downgrade it on 2/21 upgrade on 2/22
Zacks Investment Research, Inc. upgrades TITAN MEDICAL INC from SELL to HOLD.
BY Investars Analyst Actions - private
— 2:05 AM ET 02/22/2019
On February 22, 2019 Zacks Investment Research, Inc. upgraded TITAN MEDICAL INC (TTXXF) from SELL to HOLD.
no disrespect intended HC but if you feel life is short and I agree that it is ,why do you put so much time and effort ( 8 years) into this board and TMDI if you dont own the stock? I am not being sarcastic, I really am curious. I wish you well and hope we all make a profit out of this
agree 100% Flendy.
Im not sure if this came out yesterday during mkt hours..Hit my feed at 2:10 am .....Cant find any more info. These guys dont hold a lot of influence in my humble opinion but it doesnt help either just 3rd party research with no analyst name attached
I am picking away on weakness
Zacks Investment Research, Inc. downgrades TITAN MEDICAL INC from HOLD to SELL.
BY Investars Analyst Actions - private
— 2:10 AM ET 02/21/2019
On February 21, 2019 Zacks Investment Research, Inc. downgraded TITAN MEDICAL INC (TTXXF) from HOLD to SELL
Highbridge Capital files 13d-1 representing
995,000 shares of Common Stock (including 800,000 shares of Common Stock issuable upon exercise of warrants) 4.43% ..........isnt the guy who runs Highbridge on the board? this came out around noon today. I just saw it
Form SC 13G/A TITAN MEDICAL INC Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
BY 10K Wizard
— 12:11 PM ET 02/14/2019
http://archive.fast-edgar.com/20190214/AB22O2228222L2Z2222G22NHO8EVI222L2B2
http://archive.fast-edgar.com/20190212/AAZ2J22CZ222G2Z2222G2MZ8AL8BEO2732B2
options plan related 2.2 million options strike $7.48 doesnt say who gets them...Im guessing the board of directors
just did T thx Whether you buy 1 warrant or 10k they charge $82.50 ouch
Can US citizens buy the warrants on Fidelity? If not on what platform? thx in advance